Contineum Therapeutics, Inc.
For the period ended May 5, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 5, 2026 · Filed May 5, 2026
Use the contents to explore the available documents and sections.
CTNM$9.52+8.1%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except share and par value data)
(in thousands, except share and par value data)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $20,158 | $75,603 |
| Marketable securities | 226,170 | 187,293 |
| Prepaid expenses and other current assets | 6,636 | 5,021 |
| Total current assets | 252,964 | 267,917 |
| Property and equipment, net | 1,057 | 830 |
| Other long-term assets | 312 | 256 |
| Operating lease right-of-use assets | 7,016 | 7,639 |
| Total assets | $261,349 | $276,642 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,495 | $1,016 |
| Accrued expenses | 2,859 | 6,387 |
| Current portion of operating lease liabilities | 2,303 | 2,341 |
| Total current liabilities | 6,657 | 9,744 |
| Operating lease liabilities, net of current portion | 4,651 | 5,909 |
| Total liabilities | 11,308 | 15,653 |
| Commitments and contingencies | ||
| Stockholders' equity: | ||
| Class A common stock, $0.001 par value; authorized shares—200,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding shares—32,723,877 and 31,236,787 at March 31, 2026 and December 31, 2025, respectively. | 32 | 31 |
| Class B common stock, $0.001 par value; authorized shares—20,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding shares—4,662,500 and 6,083,338 at March 31, 2026 and December 31, 2025, respectively. | 5 | 6 |
| Preferred stock, $0.001 par value; authorized shares—10,000,000 at March 31, 2026 and December 31, 2025; no shares issued or outstanding at March 31, 2026 and December 31, 2025. | — | — |
| Additional paid-in-capital | 442,093 | 438,072 |
| Accumulated deficit | (191,836) | (177,380) |
| Accumulated other comprehensive income (loss) | (253) | 260 |
| Total stockholders' equity | 250,041 | 260,989 |
| Total liabilities and stockholders' equity | $261,349 | $276,642 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.